Stock Analiz

Precision Biosciences Inc. DTIL

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026

$7.57Market cap $288M
Open the interactive analysis →

Precision Biosciences Inc. (DTIL) is a healthcare company listed in the US with a market value of about $288M. In the twelve months to September 30, 2026 it had revenue of $45M and net income of -$39M, a net margin of -85.6%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 7% a year, a 5-year average ROIC of -61%.

About Precision Biosciences

Precision Biosciences is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2019. Revenue went from $11M in 2018 to $34M in 2025, growth of about 17.8% a year. It was profitable in 1 of the last 8 years in our data. Its share count rose by 338% over three years (dilution for shareholders). It spends 158% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S6.4
P/B5.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-18.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-50.1%
Revenue growth (5 yrs, per year)7.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-144.0%
ROIC (5-yr avg.)-61.1%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20252024202320222021202020192018
Revenue$45M$34M$69M$49M$25M$116M$24M$1.1B$11M
Net income-$39M-$46M$7M-$61M-$112M-$31M-$109M-$93M-$46M
Free cash flow-$52M-$66M-$59M-$86M-$49M-$16M-$92M-$96M-$66M
EPS (diluted)$-1.00$-1.19$0.35$-5.32$-12.70$-5.20$-20.90$-22.10$-29.20
Net margin-85.6%-133.4%10.4%-125.8%-444.8%-26.5%-448.9%-8.7%-423.0%
ROIC—-52.9%-40.8%-124.7%-56.3%-31.0%-157.9%-49.8%-94.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $29.40, 289% above the current price; targets range from $18.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $-2.85 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Precision Biosciences pay a dividend?

Not currently.

Is Precision Biosciences a good stock to buy?

We do not give buy or sell advice. Precision Biosciences scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.